

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT5815717

SUBMISSION TYPE:	CORRECTIVE ASSIGNMENT
NATURE OF CONVEYANCE:	Corrective Assignment to correct the ASSIGNOR NAME previously recorded on Reel 050969 Frame 0956. Assignor(s) hereby confirms the CORRECTIVE ASSIGNMENT.
CONVEYING PARTY DATA	
Name	Execution Date
NOVARTIS AG	02/25/2019
RECEIVING PARTY DATA	
Name:	ARRAY BIOPHARMA INC.
Street Address:	3200 WALNUT ST.
City:	BOULDER
State/Country:	COLORADO
Postal Code:	80301
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16580505
CORRESPONDENCE DATA	
Fax Number:	(877)769-7945
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(617) 542-5070
Email:	krahler@fr.com, apsi@fr.com
Correspondent Name:	JOHN T. KENDALL
Address Line 1:	FISH & RICHARDSON P.C.
Address Line 2:	P.O.BOX 1022
Address Line 4:	MINNEAPOLIS, MINNESOTA 55440-1022
ATTORNEY DOCKET NUMBER:	41357-0047002
NAME OF SUBMITTER:	NIKKI KRAHLER
SIGNATURE:	/Nikki Krahler/
DATE SIGNED:	11/12/2019
Total Attachments: 15	
source=41357-0047002_Assignment_NovartisAGtoArray#page1.tif	
source=41357-0047002_Assignment_NovartisAGtoArray#page2.tif	
source=41357-0047002_Assignment_NovartisAGtoArray#page3.tif	
source=41357-0047002_Assignment_NovartisAGtoArray#page4.tif	

source=41357-0047002_Assignment_NovartisAGtoArray#page5.tif
source=41357-0047002_Assignment_NovartisAGtoArray#page6.tif
source=41357-0047002_Assignment_NovartisAGtoArray#page7.tif
source=41357-0047002_Assignment_NovartisAGtoArray#page8.tif
source=41357-0047002_Assignment_NovartisAGtoArray#page9.tif
source=41357-0047002_Assignment_NovartisAGtoArray#page10.tif
source=41357-0047002_Assignment_NovartisAGtoArray#page11.tif
source=41357-0047002_Assignment_NovartisAGtoArray#page12.tif
source=41357-0047002_Assignment_NovartisAGtoArray#page13.tif
source=41357-0047002_Assignment_NovartisAGtoArray#page14.tif
source=41357-0047002_Assignment_NovartisAGtoArray#page15.tif

SECOND PATENT ASSIGNMENT AGREEMENT

This SECOND PATENT ASSIGNMENT AGREEMENT, dated February 25, 2019, and effective as of February 25, 2019, is made by and between Novartis AG, a Swiss corporation (“Assignor”), and Array BioPharma, Inc., a Delaware corporation (“Assignee”). Capitalized terms used but not defined herein will have the meanings given to them in the Asset Transfer Agreement, dated January 19, 2015 (the “Agreement”), by and between Assignor and Assignee.

WHEREAS, the Assignor is the owner of the entire right, title and interest in, and to and under the patents and/or patent applications set forth on Schedule A attached hereto (the “**Second Transferred Patents**”) and has the unrestricted right to sell, assign and transfer such patents and/or patent applications; and

WHEREAS, pursuant to the terms of the Agreement, Assignor has agreed, among other things, to transfer to Assignee said patents and/or patent applications.

NOW THEREFORE, for good and valuable consideration of the payment of the amounts set forth in the Agreement, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows:

Section 1. Assignor hereby conveys, sells, assigns, and transfers to Assignee, and Assignee hereby accepts, Assignor’s entire right, title and interest in, to and under the Second Transferred Patents, including all issuances, divisions, continuations, substitutions, continuations-in-part, re-examinations, re-issues, additions, renewals, and extensions and all rights of any kind accruing under any of the foregoing provided by Applicable Laws, by international treaties and conventions and otherwise throughout the world, and any and all accounts, contract rights, warranties, litigation claims and rights, including the right to sue for and collect upon all claims for profits and damages as a result of past infringement, if any, related to any of the foregoing, in each case whether now existing or hereafter acquired or created, whether owned, leased or licensed beneficially or of record and whether owned, leased or licensed individually, jointly or otherwise, together with the products and proceeds thereof (including license royalties and the proceeds of infringement suits), all payments and other distributions with respect thereto (all of the foregoing herein collectively referred to as the “**Second Patent Rights**”).

Section 2. Assignor hereby authorizes the Commissioners for Patents and Trademarks of the U.S. Patent and Trademark Office and other empowered officials of relevant intellectual property offices and other governmental or regulatory authorities in each jurisdiction other than the United States, to record the transfer to Assignee of all of Assignor’s rights, title and interest in, to and under the Second Patent Rights, and to issue all future registrations and other rights relating to such Second Patent Rights to Assignee.

Section 3. Assignor hereby covenants that, from time to time after the delivery of this instrument, at Assignee’s request and without further consideration, Assignor will do, execute,

acknowledge and deliver, or will cause to be done, executed, acknowledged and delivered, all such further acts, deeds, conveyances, transfers assignments, powers of attorney and assurances as reasonably may be required more effectively to convey and transfer to Assignee, and put Assignee in possession of, any of the Second Patent Rights.

Section 4. In the event of any conflict between this Second Patent Assignment Agreement and the Agreement, the provisions in the Agreement shall control. Nothing herein is intended to alter, modify, expand or diminish the terms set forth in the Agreement.

Section 5. This Second Patent Assignment Agreement is executed by, and will be binding upon, Assignee and Assignor and their respective successors and assigns for the uses and purposes set forth herein, effective immediately upon the Effective Date.

[signature page follows]

EXECUTION COPY
STRICTLY CONFIDENTIAL

IN WITNESS WHEREOF, the parties hereto have caused this Second Patent Assignment Agreement to be signed by their respective representatives thereunto duly authorized, as of the date first written above.

ARRAY BIOPHARMA, INC.

By: 
Name: Roger Dunn
Title: Interim General Counsel

NOVARTIS AG

By: 
Name: Peter R. Roth
Title: Authorized Signatory

By: 
Name: Yvonne Madawela
Title: Authorized Signatory

Schedule A

Novartis Family Number	Ctry	Type	Filing Date	Filing Number	Publication	Grant Number	Grant Date	Expiry
PAT055212-AR-NP	AR	NP	24 Jul 2013	P130102621	04 Mar 2015			24 Jul 2033
PAT055212-AU-PCT	AU	PCT	25 Jul 2013	2013295771		2013295771	24 Nov 2016	25 Jul 2033
PAT055212-BR-PCT	BR	PCT	25 Jul 2013	112014033118-9	27 Jun 2017			25 Jul 2033
PAT055212-CA-PCT	CA	PCT	25 Jul 2013	2874860				25 Jul 2033
PAT055212-CN-PCT	CN	PCT	25 Jul 2013	201380039725.5	08 Apr 2015	201380039725.5	02 Jan 2018	25 Jul 2033
PAT055212-EP-EPT	EP	EPT	25 Jul 2013	13745540.8	03 Jun 2015			25 Jul 2033
PAT055212-GC-NP	GC	NP	25 Jul 2013	P/2013/25022		GC0007482	01 Apr 2018	25 Jul 2033
PAT055212-HK-FPR	HK	FPR	27 Nov 2015	15111684.1	06 May 2016			25 Jul 2033
PAT055212-IN-PCT	IN	PCT	25 Jul 2013	376/DELNP/15	12 Jun 2015			25 Jul 2033
PAT055212-IQ-NP	IQ	NP	28 Jul 2013	258/2013		4147	12 Feb 2015	28 Jul 2033
PAT055212-JO-NP	JO	NP	25 Jul 2013	223/2013				25 Jul 2033
PAT055212-JP-PCT	JP	PCT	25 Jul 2013	2015-524444		6320379	13 Apr 2018	25 Jul 2033
PAT055212-KR-PCT	KR	PCT	25 Jul 2013	2015-7001594				25 Jul 2033
PAT055212-LB-NP	LB	NP	26 Jul 2013	10078		10078	13 Oct 2016	26 Jul 2033
PAT055212-MX-PCT	MX	PCT	25 Jul 2013	MX/A/2015/001122				25 Jul 2033

Novartis Family Number	Ctry	Type	Filing Date	Filing Number	Publication	Grant Number	Grant Date	Expiry
PAT055212-PK-NP	PK	NP	24 Jul 2013	508/13				26 Jul 2032
PAT055212-RU-PCT	RU	PCT	25 Jul 2013	2015106524				25 Jul 2033
PAT055212-TW-NP	TW	NP	25 Jul 2013	102126726	01 Apr 2014	I599357	21 Sep 2017	25 Jul 2033
PAT055212-US-PCT	US	PCT	25 Jul 2013	14/414998		9700557	11 Jul 2017	25 Jul 2033
PAT055212-US-PSP	US	PSP	26 Jul 2012	61/676134				
PAT055212-US-PSP02	US	PSP2	04 Jun 2013	61/830911				
PAT055212-VE-NP	VE	NP	25 Jul 2013	2013/965	13 Jun 2014			25 Jul 2033
PAT055212-WO-PCT	WO	PCT	25 Jul 2013	PCT/US2013/051990	30 Jan 2014			
PAT055222-AM-EAT	AM	EAT	05 Aug 2013	201590332		028420	30 Nov 2017	05 Aug 2033
PAT055222-AR-NP	AR	NP	05 Aug 2013	P130102776	18 Mar 2015			05 Aug 2033
PAT055222-AU-PCT	AU	PCT	05 Aug 2013	2013299841		2013299841	09 Mar 2017	05 Aug 2033
PAT055222-BR-PCT	BR	PCT	05 Aug 2013	112015002384-3	04 Jul 2017			05 Aug 2033
PAT055222-BY-EAT	BY	EAT	05 Aug 2013	201590332		028420	30 Nov 2017	05 Aug 2033
PAT055222-CA-PCT	CA	PCT	05 Aug 2013	2879548				05 Aug 2033
PAT055222-CL-PCT	CL	PCT	05 Aug 2013	294/2015				05 Aug 2033
PAT055222-CN-PCT	CN	PCT	05 Aug 2013	201380042229.5	15 Apr 2015	201380042229.5	27 Jun 2017	05 Aug 2033
PAT055222-CO-PCT	CO	PCT	05 Aug 2013	15024921				05 Aug 2033

Novartis Family Number	Ctry	Type	Filing Date	Filing Number	Publication	Grant Number	Grant Date	Expiry
PAT055222-DZ-PCT	DZ	PCT	05 Aug 2013	150100		9276	28 Dec 2016	05 Aug 2033
PAT055222-EA-EAT	EA	EAT	05 Aug 2013	201590332		028420	30 Nov 2017	05 Aug 2033
PAT055222-EC-PCT	EC	PCT	05 Aug 2013	IEPI-2015-8695				05 Aug 2033
PAT055222-EG-PCT	EG	PCT	05 Aug 2013	144/2015				05 Aug 2033
PAT055222-EP-EPT	EP	EPT	05 Aug 2013	13748243.6	17 Jun 2015			05 Aug 2033
PAT055222-GC-NP	GC	NP	13 Aug 2013	2013-25137		GC0008991	25 Oct 2018	13 Aug 2033
PAT055222-GT-PCT	GT	PCT	05 Aug 2013	A201500025	28 Sep 2017			05 Aug 2033
PAT055222-HK-FPR	HK	FPR	18 Jun 2015	15105815.5	11 Dec 2015			05 Aug 2033
PAT055222-ID-PCT	ID	PCT	05 Aug 2013	P00201500466	24 Feb 2017			05 Aug 2033
PAT055222-IL-PCT	IL	PCT	05 Aug 2013	236934				05 Aug 2033
PAT055222-IN-PCT	IN	PCT	05 Aug 2013	450/DELNP/15	26 Jun 2015			05 Aug 2033
PAT055222-IQ-NP	IQ	NP	04 Aug 2013	266/2013		4009	04 Aug 2014	04 Aug 2033
PAT055222-JO-NP	JO	NP	06 Aug 2013	236/2013				06 Aug 2033
PAT055222-JP-PCT	JP	PCT	05 Aug 2013	2015-526606		6342396	25 May 2018	05 Aug 2033
PAT055222-JP-PCTD	JP	PCTD	09 Feb 2018	2018-022248	12 Jul 2018			05 Aug 2033
PAT055222-KG-EAT	KG	EAT	05 Aug 2013	201590332		028420	30 Nov 2017	05 Aug 2033
PAT055222-KR-PCT	KR	PCT	05 Aug 2013	2015-7002982				05 Aug 2033
PAT055222-KZ-EAT	KZ	EAT	05 Aug 2013	201590332		028420	30 Nov 2017	05 Aug 2033

Novartis Family Number	Ctry	Type	Filing Date	Filing Number	Publication	Grant Number	Grant Date	Expiry
PAT055222-LB-NP	LB	NP	06 Aug 2013	10090		10090	13 Oct 2016	06 Aug 2033
PAT055222-MA-PCT	MA	PCT	05 Aug 2013	PV37829		37829	05 Feb 2018	05 Aug 2033
PAT055222-MO-FPR	MO	FPR	18 Sep 2017	J/002741		J/002741	14 Nov 2017	05 Aug 2033
PAT055222-MX-PCT	MX	PCT	05 Aug 2013	MX/A/2015/001732				05 Aug 2033
PAT055222-MY-PCT	MY	PCT	05 Aug 2013	PI2015000102				05 Aug 2033
PAT055222-NZ-PCT	NZ	PCT	05 Aug 2013	703940		703940	31 Jul 2018	05 Aug 2033
PAT055222-PE-PCT	PE	PCT	05 Aug 2013	000130-2015/DIN	20 May 2015			05 Aug 2033
PAT055222-PH-PCT	PH	PCT	05 Aug 2013	1-2015-500246	13 Feb 2014	1-2015-500246	09 May 2017	05 Aug 2033
PAT055222-PK-NP	PK	NP	07 Aug 2013	539/2013				07 Aug 2032
PAT055222-RU-EAT	RU	EAT	05 Aug 2013	201590332		028420	30 Nov 2017	05 Aug 2033
PAT055222-SG-PCT	SG	PCT	05 Aug 2013	11201500321Y		11201500321Y	19 Jul 2016	05 Aug 2033
PAT055222-TH-PCT	TH	PCT	05 Aug 2013	1501000631	02 Mar 2018			05 Aug 2033
PAT055222-TN-PCT	TN	PCT	05 Aug 2013	TN2015/0027				05 Aug 2033
PAT055222-TW-NP	TW	NP	06 Aug 2013	102128165	16 Mar 2014	I607754	11 Dec 2017	06 Aug 2033
PAT055222-UA-PCT	UA	PCT	05 Aug 2013	a201500424		115786	26 Dec 2017	05 Aug 2033
PAT055222-US-PCT	US	PCT	05 Aug 2013	14/419256	24 Sep 2015	9474754	25 Oct 2016	05 Aug 2033
PAT055222-US-PSP	US	PSP	07 Aug 2012	61/680473				07 Aug 2013
PAT055222-VE-NP	VE	NP	06 Aug 2013	2013/1006	18 Jul 2014			06 Aug 2033

Novartis Family Number	Ctry	Type	Filing Date	Filing Number	Publication	Grant Number	Grant Date	Expiry
PAT055222-VN-PCT	VN	PCT	05 Aug 2013	1-2015-00691	25 May 2015			05 Aug 2033
PAT055222-WO-PCT	WO	PCT	05 Aug 2013	PCT/US2013/053619	13 Feb 2014			
PAT055222-ZA-PCT	ZA	PCT	05 Aug 2013	2015/00375				05 Aug 2033
PAT055655-AR-NP	AR	NP	20 Mar 2014	P140101311	04 Nov 2015			20 Mar 2034
PAT055655-AU-PCT	AU	PCT	19 Mar 2014	2014233805				19 Mar 2034
PAT055655-BR-PCT	BR	PCT	19 Mar 2014	112015023483-6	18 Jul 2017			19 Mar 2034
PAT055655-CA-PCT	CA	PCT	19 Mar 2014	2907704				19 Mar 2034
PAT055655-CL-PCT	CL	PCT	19 Mar 2014	2015-02807				19 Mar 2034
PAT055655-CL-PCTD	CL	PCTD	22 May 2018	2018/01371	07 Sep 2018			22 May 2038
PAT055655-CN-PCT	CN	PCT	19 Mar 2014	201480026686.X	30 Dec 2015			19 Mar 2034
PAT055655-CO-PCT	CO	PCT	19 Mar 2014	15247930	31 May 2016			19 Mar 2034
PAT055655-DZ-PCT	DZ	PCT	19 Mar 2014	150646				19 Mar 2034
PAT055655-EA-EAT	EA	EAT	19 Mar 2014	201591842	29 Jan 2016			19 Mar 2034
PAT055655-EC-PCT	EC	PCT	19 Mar 2014	IEPI-2015-44248				19 Mar 2034
PAT055655-EG-PCT	EG	PCT	19 Mar 2014	1420/2015				19 Mar 2034
PAT055655-EP-EPT	EP	EPT	19 Mar 2014	14715440.5	27 Jan 2016			19 Mar 2034
PAT055655-GC-DIV	GC	DIV	17 Oct 2018	2014-36235				20 Mar 2034

Novartis Family Number	Ctry	Type	Filing Date	Filing Number	Publication	Grant Number	Grant Date	Expiry
PAT055655-GC-NP	GC	NP	20 Mar 2014	2014-26862				20 Mar 2034
PAT055655-GT-PCT	GT	PCT	19 Mar 2014	PI-2015-000249				19 Mar 2034
PAT055655-HK-FPR	HK	FPR	23 Feb 2016	16102024.8	22 Jul 2016			19 Mar 2034
PAT055655-ID-PCT	ID	PCT	19 Mar 2014	P-00201506685	18 Apr 2017			19 Mar 2034
PAT055655-IL-PCT	IL	PCT	19 Mar 2014	241188				19 Mar 2034
PAT055655-IN-PCT	IN	PCT	19 Mar 2014	5980/CHENP/2015	01 Jul 2016			19 Mar 2034
PAT055655-IQ-NP	IQ	NP	13 Mar 2014	87/2014		4658	10 Aug 2016	13 Mar 2034
PAT055655-JO-NP	JO	NP	20 Mar 2014	128/2014				20 Mar 2034
PAT055655-JP-PCT	JP	PCT	19 Mar 2014	2016-503768		6449234	14 Dec 2018	19 Mar 2034
PAT055655-JP-PCTID	JP	PCTID	04 Dec 2018					
PAT055655-KR-PCT	KR	PCT	19 Mar 2014	2015-7026781	25 Nov 2015			19 Mar 2034
PAT055655-LB-NP	LB	NP	20 Mar 2014	10334		10334	17 Jan 2017	20 Mar 2034
PAT055655-MA-PCT	MA	PCT	19 Mar 2014	PV/38522				19 Mar 2034
PAT055655-MO-FPR	MO	FPR						
PAT055655-MX-PCT	MX	PCT	19 Mar 2014	MX/a/2015/013466	11 Jul 2016			19 Mar 2034
PAT055655-MY-PCT	MY	PCT	19 Mar 2014	PI2015002402				19 Mar 2034
PAT055655-NZ-PCT	NZ	PCT	19 Mar 2014	712184				19 Mar 2034
PAT055655-PE-PCT	PE	PCT	19 Mar 2014	2056-2015	20 Dec 2015			19 Mar 2034

Novartis Family Number	Ctry	Type	Filing Date	Filing Number	Publication	Grant Number	Grant Date	Expiry
PAT055655-PH-PCT	PH	PCT	19 Mar 2014	1-2015-502040				19 Mar 2034
PAT055655-PK-NP	PK	NP	20 Mar 2014	264/2014				21 Mar 2033
PAT055655-SG-PCT	SG	PCT	19 Mar 2014	11201507730U				19 Mar 2034
PAT055655-TH-PCT	TH	PCT	19 Mar 2014	1501005626				19 Mar 2034
PAT055655-TN-PCT	TN	PCT	19 Mar 2014	TN2015/0389				19 Mar 2034
PAT055655-TW-NP	TW	NP	20 Mar 2014	103110598	01 Nov 2014	I603734	01 Nov 2017	20 Mar 2034
PAT055655-UA-PCT	UA	PCT	19 Mar 2014	a201510275				19 Mar 2034
PAT055655-US-PCT	US	PCT	19 Mar 2014	14/777873	13 Oct 2016	9913844	13 Mar 2018	19 Mar 2034
PAT055655-US-PCTD	US	PCTD	19 Jan 2018	15/875031	09 Aug 2018			19 Mar 2034
PAT055655-US-PSP	US	PSP	21 Mar 2013	61/804056				21 Mar 2014
PAT055655-VE-NP	VE	NP	19 Mar 2014	2014/00421				19 Mar 2034
PAT055655-VN-PCT	VN	PCT	19 Mar 2014	1-2015-03311				19 Mar 2034
PAT055655-WO-PCT	WO	PCT	19 Mar 2014	PCT/IB2014/059975	25 Sep 2014			
PAT055655-ZA-PCT	ZA	PCT	19 Mar 2014	2015/06693		2015/06693	28 Feb 2018	19 Mar 2034
PAT055655-ZA-PCTD	ZA	PCTD	19 Jan 2018	2018/00424				19 Mar 2034
PAT054892-AU-PCT	AU	PCT	09 Nov 2012	2012335663		2012335663	07 Apr 2016	9 Nov 2032
PAT054892-BR-PCT	BR	PCT	09 Nov 2012	112014011223.1	09 May 2017			9 Nov 2032

Novartis Family Number	Ctry	Type	Filing Date	Filing Number	Publication	Grant Number	Grant Date	Expiry
PAT054892-CA-PCT	CA	PCT	09 Nov 2012	2855243				9 Nov 2032
PAT054892-CN-PCT	CN	PCT	09 Nov 2012	201280054663.0	09 Jul 2014			9 Nov 2032
PAT054892-CN-PCTD	CN		09 Nov 2012	201810135736.8				9 Nov 2032
PAT054892-EP-EPT	EP	EPT	09 Nov 2012	12795175.4	17 Sep 2014	2776037	9 Jan 2019	9 Nov 2032
PAT054892-HK-FPR	HK	FPR	10 Dec 2014	14112437.0				9 Nov 2032
PAT054892-JP-PCT	JP	PCT	09 Nov 2012	2014-541283	11 Dec 2014	2014533272	2 June 2017	9 Nov 2032
PAT054892-MX-PCT	MX	PCT	09 Nov 2012	MX/A/14/005726	17 Jun 2014			9 Nov 2032
PAT054892-RU-PCT	RU	PCT	09 Nov 2012	2014117707	20 Dec 2015	2622015	8 June 2017	9 Nov 2032
PAT054892-US-PCT	US	PCT	09 Nov 2012	14/355903	18 Sep 2014			9 Nov 2032
PAT054892-US-PSP	US	PSP	11 Nov 2011	61/558619				11 Nov 2012
PAT054892-WO-PCT	WO	PCT	09 Nov 2012	PCT/US2012/064269	16 May 2013			
	US	PSP	03 Jun 2016	62/345,389				03 Jun 2017
	WO	PCT	02 Jun 2017	PCT/US2017/035653	07 Dec 2017			
	AU		02 Jun 2017					02 Jun 2037
	BR		02 Jun 2017	BR112018074941-9				02 Jun 2037
	CA		02 Jun 2017	3026361				02 Jun 2037

<i>Novartis Family Number</i>	<i>Ctry</i>	<i>Type</i>	<i>Filing Date</i>	<i>Filing Number</i>	<i>Publication</i>	<i>Grant Number</i>	<i>Grant Date</i>	<i>Expiry</i>
	CL		02 Jun 2017	201803421				02 Jun 2037
	CN		02 Jun 2017					02 Jun 2037
	CO		02 Jun 2017	NC2019/0000010				02 Jun 2037
	CR		02 Jun 2017	2019-0002				02 Jun 2037
	EG		02 Jun 2017	1923/2018				02 Jun 2037
	EP		02 Jun 2017	17807555.2				02 Jun 2037
	ID		02 Jun 2017	PID201811156				
	IL		02 Jun 2017	263431				02 Jun 2037
	IN		02 Jun 2017	201917000183				02 Jun 2037
	JP		02 Jun 2017					02 Jun 2037
	KR		02 Jun 2017	10-2018-7037798				02 Jun 2037
	MX		02 Jun 2017					02 Jun 2037
	MY		02 Jun 2017					02 Jun 2037
	NZ		02 Jun 2017					02 Jun 2037
	PH		02 Jun 2017	1-2018-502549				02 Jun 2037
	RU		02 Jun 2017					02 Jun 2037

<i>Novartis Family Number</i>	<i>Ctry</i>	<i>Type</i>	<i>Filing Date</i>	<i>Filing Number</i>	<i>Publication</i>	<i>Grant Number</i>	<i>Grant Date</i>	<i>Expiry</i>
	SG		02 Jun 2017	11201810793X				02 Jun 2037
	TH		02 Jun 2017					02 Jun 2037
	UA		02 Jun 2017	a 2018 13074				02 Jun 2037
	US		02 Jun 2017	16/208,172				02 Jun 2037
	ZA		02 Jun 2017					02 Jun 2037

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
NOVARTIS PHARMA AG	02/25/2019
RECEIVING PARTY DATA	
Name:	ARRAY BIOPHARMA INC.
Street Address:	3200 WALNUT ST.
City:	BOULDER
State/Country:	COLORADO
Postal Code:	80301
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16580505
CORRESPONDENCE DATA	
Fax Number:	(877)769-7945
Phone:	(617) 542-5070
Email:	krahler@fr.com, apsi@fr.com
Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.	
Correspondent Name:	JOHN T. KENDALL
Address Line 1:	FISH & RICHARDSON P.C.
Address Line 2:	P.O.BOX 1022
Address Line 4:	MINNEAPOLIS, MINNESOTA 55440-1022
ATTORNEY DOCKET NUMBER:	41357-0047002
NAME OF SUBMITTER:	NIKKI KRAHLER
Signature:	/Nikki Krahler/
Date:	11/11/2019
Total Attachments: 13 source=41357-0047002_Assignment_NovartisAGtoArray#page1.tif	

RECEIPT INFORMATION

PATENT

REEL: 050990 FRAME: 0939